ABSTRACT
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by a decrease in the airways diameter that increases their resistance to airflow (1) . Unexplained weight loss, commonly observed in patients with COPD, is clinically important because it is an independent risk factor of mortality in these patients (2) . Cachectic patients with COPD show abnormalities of the autonomic nervous system, neuroendocrine function, and energy expenditure (3) . However, its pathophysiologic mechanisms are poorly understood (4) .
Leptin is a peptide hormone secreted mainly by white adipose tissue. Its level is regulated by several factors as starvation and hormones such as insulin (5) and ovarian sex steroids (6) stimulate leptin secretion. Also, Glucocorticoids
and testosterone (6) have an inverse relationship with leptin. It acts on hypothalamic centers to regulate food intake and energy expenditure. Leptin is, also, involved in the regulation of various other physiological processes including carbohydrate and lipid metabolism, gastrointestinal and cardiovascular function, inflammation, immune response and reproduction (8) . Serum leptin concentration is proportionated to the amount of white adipose tissue and is markedly increased in obese individuals (9) . The reported rise of blood leptin concentrations following acute infection and in chronic inflammation suggests that leptin may actively participate in the immune network and host defense (9) . Indeed, leptin levels are rapidly increased by many acute phase cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) (10) . and the central nervous system (27) . In addition, plasma NO level is affected by factors other than NO production such as dietary nitrates and renal excretory function.
The present study was undertaken to investigate the association of plasma leptin levels and NO metabolites (nitrites plus nitrates) levels in COPD. 
PATIENTS & METHODS

Sample Collection and isolation of plasma
Blood was obtained from all subjects in the overnight fasting state (from 9:00 PM on the previous night) by venipuncture at 9.00 AM. Blood was collected in glass tubes containing ethylenediaminetetra acetic acid. Blood was centrifuged at 1600g for 15 min at 4°C, and plasma was collected and stored at -70°C until analysis.
Leptin Assay
The DSL-10-23100 ACTIVE® Human Leptin ELISA is an enzymatically amplified "two-step" sandwich-type immunoassay (30).
Nitric oxide metabolites Assay
NO levels were measured as the concentration of nitrate plus nitrite in the plasma in two step process. The first step is the reduction of nitrate (NO 3 ) to nitrite (NO 2 ) by nitrate reductase. The second step is the addition of the Griess Reagent which converts nitrite into deep purple azo compound.
The sample was deproteinized with ZnSO4, and the concentration of nitrite was measured spectrophotometrically at 540 nm using the Griess reaction with commercial kit (Cayman chemical, catalog No 780001, Germany).
Statistical Analysis:
Values were expressed as mean, medians (range) and ± standard deviation (SD). For both serum leptin and NO in comparisons of controls and COPD patients, unpaired Student's t-test was used. Differences with p values ≤ 0.05 were considered significant by using SPSS software (release 10.0).
RESULTS
Thirty three patients (male n= 18 and female n=15) above forty with mild to severe COPD (FEV 1 range 30-80% predicted) were included in the present study. The average age in years in COPD was 40. Leptin was detected in serum samples of control group and COPD patients ( fig.1A ) . The mean value of serum leptin was significantly lower in COPD patients (10.3 ± 3.9 ng/ml) than that in control group (13.9 ± 1.9 ng/ml). Also, the mean of serum NO was significantly lower in COPD patients (16.9 ± 5.2µmo l/ L) than that in control group (22.7 ± 2.6µmo l/ L) (figure 1B). In COPD patients, serum leptin and NO levels were significantly lower in both male and female groups compared to the mean of both male and female control group (Table 2) . To compare the serum leptin level to the change in the BMI, levels of serum leptin was divided on BMI.
Leptin / BMI of each case and that value had no significant change in male and female control group compared to the corresponding sex of COPD group (Table 2) . High serum leptin levels and obesity (high body weight) are associated with female than in male in both control and COPD. Serum leptin is produced by adipose tissue leptin, so its level is higher in women than in men (37) . Also, the expression of serum leptin is higher in female than male and this may be due to the effect of sex hormones where it can be inhibited by testosterone and increased by ovarian sex hormones (6) . Circulating leptin levels are lower in COPD patients compared with healthy controls but that level was associated with low body weight probably due to reduced white adipose tissue. Apart from its satiety effect, leptin is, also, recognized to induce an inflammatory response (38) . Elevated serum leptin in COPD patients was partially explained by acute exacerbation of COPD (36) or systemic glucocorticosteroid administration (39) . The low serum leptin in COPD may be related to have one of the following reasons. First, hypoxic COPD patients were found to have impaired glucose tolerance and hyperinsulinemia (5) .
Second hypoxic gonads and low female sex hormone (6) but it is most probably related to low body weight. In addition, leptin potentates expression of nitric oxide synthase in murine macrophage (40) . The significant association between low total NO and COPD may be related to the pathogenesis of COPD. Bronchial constriction (41) , increasing of pulmonary vascular resistance with pulmonary hypertension (42) and decreasing in ciliary beat frequency (43) with accumulation of intra-bronchiolar stick secretion are the pathology with COPD.
NO had many pharmacological effects on the airways, first, it relaxed the pulmonary artery which preconstricted with hypoxia (12) . NO was shown to induce pulmonary vasodilatation (44) . Endogenous NO modulates cholinergic neurotransmission by inhibiting acetylcholine release (41) or reducing the release of cyclooxygenase products (40) to perform its bronchodilator action on airway smooth muscle. Nonselective β 2 -adrenoceptor agonist isoprenaline was shown to up-regulate the ciliary beat frequency by a NO-dependent mechanism (43) . An increase in ciliary beat frequency would aid in the clearance of harmful substances contained within the mucus mesh.
In conclusion, in spite of low circulating leptin in COPD, that change is related to low BMI. Low serum leptin is associated with low concentrations of serum NO in these patients. Low level of serum NO (not leptin) has a role in the pathogenesis of COPD. Role of serum NO in the prognosis and progression of COPD needs further study. 
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